Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:(%22Essai clinique phase II%22)

Filter

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Origin

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 922699

  • Page / 36908
Export

Selection :

  • and

Clinical development of anticancer agents. A National Cancer Institute perspective = Développement de l'utilisation clinique de substances anticancéreuses. Une perspective du National Cancer InstituteMARSONI, S; WITTES, R.Cancer treatment reports. 1984, Vol 68, Num 1, pp 77-85, issn 0361-5960Article

Design Issues in Randomized Phase II/III TrialsKORN, Edward L; FREIDLIN, Boris; ABRAMS, Jeffrey S et al.Journal of clinical oncology. 2012, Vol 30, Num 6, pp 667-671, issn 0732-183X, 5 p.Article

Les ellipticines et aza-ellipticines = Ellipticins and aza-ellipticinsGISSELBRECHT, C; MARTY, M; MIGNOT, L et al.Actualités hématologiques. 1984, Vol 18, pp 193-207, issn 0567-8757Article

Characterization and multiparameter analysis of visual adverse events in Irofulven single-agent Phase I and II trialsRAYMOND, Eric; KAHATT, Carmen; CULLEN, Michael et al.Clinical cancer research. 2004, Vol 10, Num 22, pp 7566-7574, issn 1078-0432, 9 p.Article

CLINICAL TRIALSOF NEW DRUGS.DOLLERY CT; WADE OL; TURNER P et al.1977; J. R. COLL. PHYSICIANS LONDON; G.B.; DA. 1977; VOL. 11; NO 3; PP. 226-233; BIBL. 1 REF.Article

The unclear zone in phase II clinical trialsALLEGRO, Sabrina; POND, Gregory R; HOTTE, Sébastien J et al.European journal of cancer (1990). 2010, Vol 46, Num 13, pp 2408-2413, issn 0959-8049, 6 p.Article

Méthodologie des essais cliniques en cancérologie : médicaments anticancéreux (2e partie) = Design of clinical trials in oncologyTRANCHAND, Brigitte; CHABAUD, Sylvie; COLOMBAN, Olivier et al.La Lettre du pharmacologue (Boulogne). 2008, Vol 22, Num 3, pp 98-110, issn 0984-452X, 13 p.Article

Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC#4366650 and cryopreserved autologous marrow transplantation for retractory cancer: a phase I-II study = BCNU à haute dose et greffe autologue de moelle cryocongelée dans les tumeurs résistantes. Une étude phase I-IIPHILLIPS, G. L; FAY, J. W; HERZIG, G. P et al.Cancer. 1983, Vol 52, Num 10, pp 1792-1802, issn 0008-543XArticle

A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-lnduced neuromuscular blockGROUDINE, Scott B; SOTO, Roy; LIEN, Cynthia et al.Anesthesia and analgesia. 2007, Vol 104, Num 3, pp 555-562, issn 0003-2999, 8 p.Article

Early clinical trials of mitoxantrone = Premiers essais cliniques de la mitoxantroneBODEY, G. P; VALDIVIESO, M; HWEE-YONG YAP et al.Monograph series of the European Organization for Research on Treatment of Cancer. 1983, Vol 12, pp 103-114, issn 0146-0447Article

Design issues of randomized phase II trials and a proposal for phase II screening trialsRUBINSTEIN, Lawrence V; KORN, Edward L; FREIDLIN, Boris et al.Journal of clinical oncology. 2005, Vol 23, Num 28, pp 7199-7206, issn 0732-183X, 8 p.Article

Comment faire évoluer le paradigme du développement clinique et son découpage en phases I, II, IIIBAMBERGER, Marion; MOORE, Nicholas; LECHAT, Philippe et al.Thérapie (Paris). 2011, Vol 66, Num 4, pp 327-330, issn 0040-5957, 4 p.Article

Widening eligibility to phase II trials: constant arcsine difference phase II trialsA'HERN, Roger P.Controlled clinical trials. 2004, Vol 25, Num 3, pp 251-264, issn 0197-2456, 14 p.Article

Randomized Phase II Trials: Inevitable or Inadvisable?GAN, Hui K; GROTHEY, Axel; POND, Gregory R et al.Journal of clinical oncology. 2010, Vol 28, Num 15, pp 2641-2647, issn 0732-183X, 7 p.Article

BIOLOGIC RESPONSE-MODIFYING AGENTS: WHAT IS AN APPROPRIATE PHASE I-II STRATEGY.CARTER SK.1980; CANCER IMMUNOL. IMMUNOTHER.; ISSN 0340-7004; DEU; DA. 1980; VOL. 8; NO 4; PP. 207-210; BIBL. 4 REF.Article

CLINICAL TRIALS IN CANCER CHEMOTHERAPY.CARTER SK.1977; CANCER; U.S.A.; DA. 1977; VOL. 40; NO 1, SUPPL.; PP. 544-557; BIBL. 1 P. 1/2Article

MANAGEMENT OF TRIALS IN THE DEVELOPMENT OF CANCER CHEMOTHERAPY.WILLIAMS CJ; CARTER SK.1978; BRIT. J. CANCER; GBR; DA. 1978; VOL. 37; NO 3; PP. 434-447; BIBL. 24 REF.Article

Les essais cliniques = Clinical trialsZIVIN, J.Pour la science. 2000, Num 272, pp 100-105, issn 0153-4092Article

Journées de pharmacogie cliniqueThérapie (Paris). 1992, Vol 47, Num 5, pp 455-465, issn 0040-5957Conference Proceedings

Optimising the design of phase II oncology trials : The importance of randomisationRATAIN, Mark J; SARGENT, Daniel J.European journal of cancer (1990). 2009, Vol 45, Num 2, pp 275-280, issn 0959-8049, 6 p.Article

Assessing the success probability of a Phase III clinical trial based on Phase II dataZHENG SU.Contemporary clinical trials. 2010, Vol 31, Num 6, pp 620-623, issn 1551-7144, 4 p.Article

Phase I-II trial of prone accelerated intensity modulated radiation therapy to the breast to optimally spare normal tissueFORMENTI, Silvia C; GIDEA-ADDEO, Daniela; GOLDBERG, Judith D et al.Journal of clinical oncology. 2007, Vol 25, Num 16, pp 2236-2242, issn 0732-183X, 7 p.Article

Phase II/III randomized trial of TCH346 in patients with ALSMILLER, R; BRADLEY, W; STRONG, M et al.Neurology. 2007, Vol 69, Num 8, pp 776-784, issn 0028-3878, 9 p.Article

Proceedings/Symposium on the development of a drug, LHRH agonists: 3rd. international congress of andrology, Boston MA, April 27-May 2, 1985VICKERY, B. H.Journal of andrology. 1987, Vol 8, Num 1, pp S.1-S.31, issn 0196-3635Conference Proceedings

Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials : What Are the Predictors for Success?CHAN, John K; UEDA, Stefanie M; SUGIYAMA, Valerie E et al.Journal of clinical oncology. 2008, Vol 26, Num 9, pp 1511-1518, issn 0732-183X, 8 p.Article

  • Page / 36908